Bicara Therapeutics Funding & Investors
Cambridge, MA
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.
bicara.comTotal Amount Raised: $313,000,000
Bicara Therapeutics Funding Rounds
IPO
Unknown
Series C
$165,000,000
Series C Investors
BraidwellThe Rise FundTPGDeerfield ManagementAisling CapitalFairmont CapitalRed Tree Venture CapitalAcorn BioventuresInvusTHE CATALYTIC IMPACT FOUNDATION (CIF)Eight Roads VenturesRA Capital ManagementOmega Fund ManagementBioqube VenturesPiper Heartland Healthcare CapitalPremjiInvestHenderson Global InvestorsF-Prime CapitalSeries B
$108,000,000
Series B Investors
RA Capital ManagementRed Tree Venture CapitalF-Prime CapitalAcorn BioventuresPremjiInvestPiper Heartland Healthcare CapitalHenderson Global InvestorsEight Roads VenturesBioqube VenturesOmega Fund ManagementInvusTHE CATALYTIC IMPACT FOUNDATION (CIF)Seed
$40,000,000
Seed Investors
Biocon
Funding info provided by Diffbot.